Verona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
News Medical1d
Addressing COPD and metabolic syndrome requires comprehensive research efforts
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
AerWave Medical concludes study of ultrasound therapy for COPD
The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
Downtown Amarillo Library temporarily closing for city work
The Downtown Amarillo Library will be temporarily closed for Wednesday evening and Thursday due to a city water main issue.
Amarillo doctor explains new procedure that offers hope for COPD patients
The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...
Science Daily1d
COPD News
Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...
Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...
pulmonologyadvisor2d
Benralizumab Improves Eosinophilic Exacerbations in Asthma, COPD
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
AerWave Completes First-in-Human Study to Advance Disease-Modifying Ultrasound-Based Therapy for COPD and Asthma
Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) ...